Overview of Recent Clinical Trials of Acellular Pertussis Vaccines

This publication has 16 references indexed in Scilit:

• Comparative Efficacy of the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine and Lederle Whole-Cell Component DTP Vaccine in German Children After Household Exposure
  Published by American Academy of Pediatrics (AAP) ,1998
• Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines
  Vaccine, 1998
• Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
  The Lancet, 1997
• Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants
  The Pediatric Infectious Disease Journal, 1997
• Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance
  Vaccine, 1997
• A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine
  New England Journal of Medicine, 1996
• A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
  New England Journal of Medicine, 1996
• A Placebo-Controlled Trial of a Pertussis-Toxoid Vaccine
  New England Journal of Medicine, 1995
• Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance
  Vaccine, 1992
• Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial
  Vaccine, 1990